Geron Corporation

American biotechnology company

Logo of Geron Corporation

Geron Corporation is an American biotechnology company headquartered in Foster City, California. The company is primarily focused on the development of innovative therapies for the treatment of hematologic malignancies. Geron is known for its pioneering work in telomerase research and its potential applications in oncology.

History

Geron Corporation was founded in 1990 by Dr. Michael D. West, a biologist with a vision to explore the potential of telomeres and telomerase in aging and cancer. The company initially focused on the development of telomerase inhibitors as a therapeutic approach to cancer treatment. Over the years, Geron has evolved its research and development strategies, concentrating on the clinical advancement of its lead drug candidate, imetelstat.

Research and Development

Geron's research is centered around the enzyme telomerase, which is responsible for maintaining the length of telomeres, the protective caps at the ends of chromosomes. In most somatic cells, telomerase activity is low or absent, leading to progressive telomere shortening and cellular aging. However, in many cancer cells, telomerase is reactivated, allowing these cells to divide indefinitely.

Imetelstat

Imetelstat is Geron's lead drug candidate, a first-in-class telomerase inhibitor. It is being developed for the treatment of hematologic malignancies, including myelofibrosis and myelodysplastic syndromes. Imetelstat works by targeting the RNA template component of telomerase, thereby inhibiting its activity and leading to telomere shortening in cancer cells. This can result in the reduction of cancer cell proliferation and potentially lead to apoptosis.

Clinical Trials

Geron has conducted several clinical trials to evaluate the safety and efficacy of imetelstat. These trials have shown promising results, particularly in patients with myelofibrosis and myelodysplastic syndromes who have limited treatment options. The company continues to advance its clinical programs, aiming to bring new therapeutic options to patients with unmet medical needs.

Partnerships and Collaborations

Geron has engaged in various partnerships and collaborations to enhance its research and development efforts. Notably, the company had a collaboration with Janssen Biotech, a subsidiary of Johnson & Johnson, to develop and commercialize imetelstat. Although this collaboration ended in 2018, Geron regained the global rights to imetelstat and continues to pursue its development independently.

Future Directions

Looking ahead, Geron aims to expand its clinical development programs and explore additional indications for imetelstat. The company is also interested in investigating other potential applications of telomerase inhibition in oncology and beyond.

Related pages

• Biotechnology
• Telomerase
• Cancer
• Hematologic malignancy